Jonathan Violin
CIK 1730615 · Chief Executive Officer · last filed 2026-06-03
Jonathan Violin is a Chief Executive Officer who has filed 26 SEC Form 4 insider transactions across 7 companies since 2018. The most recent filing, for GLYC, was dated Jun 3, 2026. Across all open-market trades the lifetime net is −$6.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.86M
7
26
-$6.11M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | — | $15.70 | — | $0 | 2 | 2026-06-03 |
| DNTH | Director | — | $82.07 | — | $0 | 4 | 2026-05-22 |
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | 0 | $12.58 | $0 | $0 | 7 | 2026-01-23 |
| VRDN | Chief Executive Officer | 480,905 | $16.35 | $7.86M | -$6.11M | 9 | 2023-02-07 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 2 | 2021-06-02 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | President and COO | 50,124 | — | — | $0 | 1 | 2020-10-30 |
| TRVN | SVP-Scientific Affairs & IR | — | $0.01 | — | $0 | 1 | 2018-03-02 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2026-01-23 | Astria Therapeutics, Inc. (ATXS) Delisted | Disp (D) | −263,321 | $0 | EDGAR |
| 2025-06-23 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-28 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2023-09-13 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2023-06-06 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |